Clinical trial
Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine…
NCT00406562 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00406562 |
|---|---|
| Title | Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. |
| Official title | Open, Booster Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Administered to Healthy Chinese Children 6-8 Years of Age. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tetanus, Diphtheria, Acellular Pertussis |
| Intervention type | Biological |
| Interventions | Boostrix |
| Enrollment | 30 |
| Start date | Jan 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Dec 4, 2006 |
| Last update posted | Oct 27, 2016 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: